Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025


Werte in diesem Artikel
Aktien

9.30 EUR 0.20 EUR 2.20 %

GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows:

Conference call details: 


Date:                               

November 6, 2025

Time:                             

8:30 a.m. ET

URL to register phone:   

Register Here

Dial-in number:             

(888) 880-3330 (U.S.) or


(+1) (646) 357-8766 (International)

Webcast:                       

ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

Replay details:               


Date:                             

Available starting at 11:30 a.m. ET, November 6, 2025, until
11:59 p.m. ET, November 13, 2025

Dial-in number:             

(800) 770-2030 (U.S.) or


(+1) (609) 800-9909 (International)

Passcode:                 

3585070#

Webcast:                   

ir.novavax.com/events, until December 5, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.

Contacts: 

Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media
Yvonne Sprow
844-264-8571
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-third-quarter-2025-financial-results-on-november-6-2025-302599179.html

SOURCE Novavax, Inc.

Aktuelle Novavax Aktie News

Werbung

Novavax Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novavax nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
14.08.19 Novavax Buy H.C. Wainwright & Co.
11.12.18 Novavax Outperform Oppenheimer & Co. Inc.
29.03.18 Novavax Buy Seaport Global Securities
05.01.18 Novavax Buy B. Riley FBR, Inc.
20.09.16 Novavax Neutral Chardan Capital Markets

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.